B.H. Jaswanth Gowda
@qub.ac.uk
Commonwealth Scholar, School of Pharmacy
Queen's University Belfast, UK
I am a Commonwealth Research Fellow at Queen's University Belfast, UK. I have authored several research and review articles, and book chapters, in reputable national and international journals. My research primarily focuses on the development of various nano- and micro-based transdermal and ocular drug delivery systems, including microneedles, for the treatment of various disease conditions.
EDUCATION
Master of Pharmacy in Pharmaceutics
RESEARCH INTERESTS
Transdermal delivery systems, Ocular drug delivery, Microneedles, Nanoparticles, Skin cancer, Co-crystallization
Scopus Publications
Scholar Citations
Scholar h-index
Scholar i10-index
Scopus Publications
Mohammad Sameer Khan, B.H. Jaswanth Gowda, Nazeer Hasan, Garima Gupta, Tanuja Singh, Shadab Md, and Prashant Kesharwani
Elsevier BV
B. H. Jaswanth Gowda, Mohammed Gulzar Ahmed, Mohammad Ali Abdullah Almoyad, Shadma Wahab, Waleed H. Almalki, and Prashant Kesharwani
Wiley
AbstractNanosponges are unique sponge‐like carrier systems with numerous cavities and a mesh‐like network throughout their surface. They are categorized into three types based on the material of construction, i.e., polymer‐, inorganic‐, and bio‐derived material‐based nanosponges. Unlike conventional nanoparticles, nanosponges bear countless interconnected voids and mesh‐like network that enables maximum drug, imaging probe, or photosensitizer loading via absorption, encapsulation, conjugation, or complexion. The voids can be further sealed using suitable lipids or polymers to avoid leakage of drugs at the non‐target site, protect therapeutics from biological conditions, and control the release of therapeutics for a prolonged period. Recently, nanosponges have grasped the attention of researchers in the area of cancer by overcoming the drawbacks associated with the conventional delivery of immunotherapeutic, targeted therapeutic, and chemotherapeutic agents. Interestingly, several reports have also witnessed their potential in cancer theranostics. Owing to this supremacy, nanosponges could be an apt platform for cancer therapy and diagnosis. The current review discusses the general aspects, types, and preparation methods of nanosponges. In addition, the ambit of nanosponges in treating different types of cancer is meticulously discussed, along with detailed descriptions of their corresponding patents. Furthermore, the role of nanosponges in phototherapy and cancer theranostics are selectively canvassed.
Sumel Ashique, Neeraj Mishra, Sourav Mohanto, B.H. Jaswanth Gowda, Shubneesh Kumar, Amisha S. Raikar, Priya Masand, Ashish Garg, Priyanka Goswami, and Ivan Kahwa
Elsevier BV
Sagnik Nag, Oishi Mitra, Sankarganesh P, Arghyadeep Bhattacharjee, Sourav Mohanto, B.H. Jaswanth Gowda, Shinjini Kar, Sudha Ramaiah, Anand Anbarasu, and Mohammed Gulzar Ahmed
Elsevier BV
Mohammad Sameer Khan, B.H. Jaswanth Gowda, Waleed H. Almalki, Tanuja Singh, Amirhossein Sahebkar, and Prashant Kesharwani
Elsevier BV
Sanjana A, Mohammed Gulzar Ahmed, B.H. Jaswanth Gowda, and Suprith Surya
Informa UK Limited
Sourav Mohanto, Soumya Narayana, Khushboo Paresh Merai, Jahanvee Ashok Kumar, Adrija Bhunia, Umme Hani, Adel Al Fatease, B.H. Jaswanth Gowda, Sagnik Nag, Mohammed Gulzar Ahmed,et al.
Elsevier BV
Umme Hani, B. H. Jaswanth Gowda, Nazima Haider, KVRNS Ramesh, Karthika Paul, Sumel Ashique, Mohammed Gulzar Ahmed, Soumya Narayana, Sourav Mohanto, and Prashant Kesharwani
Springer Science and Business Media LLC
Blood cancer, also known as hematological malignancy, is one of the devastating types of cancer that has significantly paved its mortality mark globally. It persists as an extremely deadly cancer type and needs utmost attention owing to its negligible overall survival rate. Major challenges in the treatment of blood cancer include difficulties in early diagnosis, as well as severe side effects resulting from chemotherapy. In addition, immunotherapies and targeted therapies can be prohibitively expensive. Over the past two decades, scientists have devised a few nanoparticle-based drug delivery systems aimed at overcoming this challenge. These therapeutic strategies are engineered to augment the cellular uptake, pharmacokinetics, and effectiveness of anticancer drugs. However, there are still numerous types of nanoparticles that could potentially improve the efficacy of blood cancer treatment, while also reducing treatment costs and mitigating drug-related side effects. To the best of our knowledge, there has been limited reviews published on the use of nano-based drug delivery systems for the treatment of hematological malignancies. Therefore, we have made a concerted effort to provide a comprehensive review that draws upon recent literature and patents, with a focus on the most promising results regarding the use of nanoparticle-based approaches for the treatment of hematological malignancies. All these crucial points covered under a common title would significantly help researchers and scientists working in the area.
Sumel Ashique, Shubneesh Kumar, Afzal Hussain, Neeraj Mishra, Ashish Garg, B. H. Jaswanth Gowda, Arshad Farid, Gaurav Gupta, Kamal Dua, and Farzad Taghizadeh‑Hesary
Springer Science and Business Media LLC
Sumel Ashique, Shubneesh Kumar, Afzal Hussain, Neeraj Mishra, Ashish Garg, B. H. Jaswanth Gowda, Arshad Farid, Gaurav Gupta, Kamal Dua, and Farzad Taghizadeh-Hesary
Springer Science and Business Media LLC
Abstract Background Magnesium (Mg) has gained much importance recently because of its unique range of biological functions. It is one of the most significant micronutrients in biological systems. This review aims to outline the immune-regulating actions of Mg and its crucial role in regulating inflammation and immune response to infectious agents and malignancies. Methods We conducted a literature review on MEDLINE, PubMed, EMBASE, Web of Science to determine the impact of Mg on immune regulation in three settings of inflammation, infection, and cancer. We thoroughly examined all abstracts and full-text articles and selected the most relevant ones for inclusion in this review. Results Mg has long been associated with immunological responses, both nonspecific and specific. It plays a pivotal role in diverse immune responses by participating in multiple mechanisms. It facilitates substance P binding to lymphoblasts, promotes T helper, B cell, and macrophage responses to lymphokines, and facilitates antibody-dependent cytolysis and immune cell adherence. Besides, Mg serves as a cofactor for C'3 convertase and immunoglobulin synthesis. It additionally boasts a significant anti-cancer effect. Chronic Mg deficiency leads to enhanced baseline inflammation associated with oxidative stress, related to various age-associated morbidities. A deficiency of Mg in rodents has been observed to impact the cell-mediated immunity and synthesis of IgG adversely. This deficiency can lead to various complications, such as lymphoma, histaminosis, hypereosinophilia, increased levels of IgE, and atrophy of the thymus. The immunological consequences of Mg deficiency in humans can be influenced by the genetic regulation of Mg levels in blood cells. Mg can also mediate cell cycle progression. There has been a renewed interest in the physiology and therapeutic efficacy of Mg. However, the in-depth mechanisms, their clinical significance, and their importance in malignancies and inflammatory disorders still need to be clarified. Conclusions Mg is essential for optimal immune function and regulating inflammation. Deficiency in Mg can lead to temporary or long-term immune dysfunction. A balanced diet usually provides sufficient Mg, but supplementation may be necessary in some cases. Excessive supplementation can have negative impacts on immune function and should be avoided. This review provides an update on the importance of Mg in an immune response against cancer cells and infectious agents and how it regulates inflammation, oxidative stress, cell progression, differentiation, and apoptosis.
Leli Zeng, B. H. Jaswanth Gowda, Mohammed Gulzar Ahmed, Mohammed A. S. Abourehab, Zhe-Sheng Chen, Changhua Zhang, Jia Li, and Prashant Kesharwani
Springer Science and Business Media LLC
AbstractSkin cancer has emerged as the fifth most commonly reported cancer in the world, causing a burden on global health and the economy. The enormously rising environmental changes, industrialization, and genetic modification have further exacerbated skin cancer statistics. Current treatment modalities such as surgery, radiotherapy, conventional chemotherapy, targeted therapy, and immunotherapy are facing several issues related to cost, toxicity, and bioavailability thereby leading to declined anti-skin cancer therapeutic efficacy and poor patient compliance. In the context of overcoming this limitation, several nanotechnological advancements have been witnessed so far. Among various nanomaterials, nanoparticles have endowed exorbitant advantages by acting as both therapeutic agents and drug carriers for the remarkable treatment of skin cancer. The small size and large surface area to volume ratio of nanoparticles escalate the skin tumor uptake through their leaky vasculature resulting in enhanced therapeutic efficacy. In this context, the present review provides up to date information about different types and pathology of skin cancer, followed by their current treatment modalities and associated drawbacks. Furthermore, it meticulously discusses the role of numerous inorganic, polymer, and lipid-based nanoparticles in skin cancer therapy with subsequent descriptions of their patents and clinical trials. Graphical Abstract
Umme Hani, B. Jaswanth Gowda, A. Siddiqua, S. Wahab, Yasmin Begum, P. Sathishbabu, S. Usmani and MD Parwez Ahmed
B.H. Jaswanth Gowda, Mohammed Gulzar Ahmed, Saad Ali Alshehri, Shadma Wahab, Lalitkumar K. Vora, Raghu Raj Singh Thakur, and Prashant Kesharwani
Elsevier BV
Mohammad Banazadeh, Behzad Behnam, Narges Ashraf Ganjooei, B.H. Jaswanth Gowda, Prashant Kesharwani, and Amirhossein Sahebkar
Elsevier BV
Mohammad Sameer Khan, B.H. Jaswanth Gowda, Nazim Nasir, Shadma Wahab, Mallikarjuna Rao Pichika, Amirhossein Sahebkar, and Prashant Kesharwani
Elsevier BV
Jisan Ahamed, B.H. Jaswanth Gowda, Waleed H. Almalki, Neelima Gupta, Amirhossein Sahebkar, and Prashant Kesharwani
Elsevier BV
Soumya Narayana, Arfa Nasrine, Mohammed Gulzar Ahmed, Rokeya Sultana, B.H. Jaswanth Gowda, Suprith Surya, Mansour Almuqbil, Syed Mohammed Basheeruddin Asdaq, Sultan Alshehri, and Syed Arif Hussain
Elsevier BV
B.H. Jaswanth Gowda, Mohammed Gulzar Ahmed, Umme Hani, Prashant Kesharwani, Shadma Wahab, and Karthika Paul
Elsevier BV
B.H.J. Gowda, S. Mohanto, A. Singh, A. Bhunia, M.A. Abdelgawad, S. Ghosh, M.J. Ansari, and S. Pramanik
Elsevier BV
Umme Hani, Riyaz Ali M. Osmani, Sabina Yasmin, B. H. Jaswanth Gowda, Hissana Ather, Mohammad Yousuf Ansari, Ayesha Siddiqua, Mohammed Ghazwani, Adel Al Fatease, Ali H. Alamri,et al.
MDPI AG
Cancer has long been regarded as one of the world’s most fatal diseases, claiming the lives of countless individuals each year. Stomach cancer is a prevalent cancer that has recently reached a high number of fatalities. It continues to be one of the most fatal cancer forms, requiring immediate attention due to its low overall survival rate. Early detection and appropriate therapy are, perhaps, of the most difficult challenges in the fight against stomach cancer. We focused on positive tactics for stomach cancer therapy in this paper, and we went over the most current advancements and progressions of nanotechnology-based systems in modern drug delivery and therapies in great detail. Recent therapeutic tactics used in nanotechnology-based delivery of drugs aim to improve cellular absorption, pharmacokinetics, and anticancer drug efficacy, allowing for more precise targeting of specific agents for effective stomach cancer treatment. The current review also provides information on ongoing research aimed at improving the curative effectiveness of existing anti-stomach cancer medicines. All these crucial matters discussed under one overarching title will be extremely useful to readers who are working on developing multi-functional nano-constructs for improved diagnosis and treatment of stomach cancer.
Karthika Paul, Jaswanth Gowda B.H., and S.J. Shankar
A and V Publications
The bioanalytical evaluation of paracetamol and pamabrom study had been developed using the RP-HPLC method. The elution was done by the mobile phase containing ammonium formate and methanol. The separation was done by using the Hibar C18 column. The flow rate was adjusted to 1.0 ml/min with an injection volume of 20 µl. The wavelength of 268 nm was overlaid for analytical purposes. A volume of 25 µg/ml of internal standard (furosemide) was injected. Paracetamol and pamabrom showed retention time at 7.05 min and 10.02 min with no interference peak from internal standard showing a retention time at 11.97 min. The values of the limit of detection (LOD) and limit of quantification (LOQ) for paracetamol and pamabrom was found to be 0.03 µg/ml and 0.015 µg/ml; 0.1 µg/ml and 0.05 µg/ml respectively. The developed method was rapid, simple, accurate, precise, robust and selective. This method can be used for the simultaneous estimation of the solid oral dosage forms containing paracetmol and pamabrom in biological sample.
B.H. Jaswanth Gowda, Mohammed Gulzar Ahmed, Sampath Chinnam, Karthika Paul, Md Ashrafuzzaman, Murthy Chavali, Rekha Gahtori, Soumya Pandit, Kavindra Kumar Kesari, and Piyush Kumar Gupta
Elsevier BV
B.H. Jaswanth Gowda, Mohammed Gulzar Ahmed, Amirhossein Sahebkar, Yassine Riadi, Rahul Shukla, and Prashant Kesharwani
American Chemical Society (ACS)
Microneedles are one of the most prominent approaches capable of physically disrupting the stratum corneum without devastating the deeper tissues to deliver both small molecules and macromolecules into the viable epidermis/dermis for local/systemic effects. Over the past two decades, microneedles have caught the attention of many researchers because of their outstanding advantages over oral and parenteral drug delivery systems such as self-administration, pain-free, steady-plasma concentration maintenance, avoidance of first-pass hepatic biotransformation, and so on. So far, scientists have reported various types of microneedle patches to deliver the loaded therapeutics as soon as the microneedles are inserted into the skin, regardless of the demand for therapeutics to treat a specific condition. This way of drug delivery can lead to potential risks such as poor therapeutic efficacy or drug overdose. The stimuli-responsive microneedles are the most predominant tool to achieve the on-demand/need-based drug delivery, leading to safe and effective treatment. Various natural and synthetic polymers that can undergo significant transitions such as swelling, shrinking, dissolution, or disintegration play a pivotal role in the development of stimuli-responsive microneedles. The current Review provides brief information about the history, emergence, type, and working principles of microneedles. Furthermore, it selectively discusses various exogenous and endogenous stimuli-responsive microneedles along with their mechanism of action involved in treating different disease conditions. Collaterally, the emergence of "closed-loop" combinatorial stimuli-responsive microneedle patches for precise delivery of therapeutics is meticulously canvassed. Subsequently, it covers the patents of different stimuli-responsive microneedles and further highlights the existing challenges and future perspectives concerning clinical application and large-scale production.
B.H. Jaswanth Gowda, Mohammed Gulzar Ahmed, and Akhter Husain
Elsevier BV